Fate Therapeutics (FATE) News Today $1.27 +0.02 (+1.60%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Down 8.1% in DecemberFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 11,200,000 shares, a decrease of 8.1% from the December 15th total of 12,190,000 shares. Based on an average daily volume of 2,950,000 shares, the short-interest ratio is presently 3.8 days.January 18 at 2:21 PM | marketbeat.comJPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE)JPMorgan Chase & Co. raised its stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 18.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,837,304 shares of the biopharmaceutical company's stock after buying an aJanuary 16 at 3:13 AM | marketbeat.comClinical trial: Off-the-shelf immunotherapy shows promise for B-cell lymphomaJanuary 14, 2025 | msn.comBarclays Issues a Buy Rating on Fate Therapeutics (FATE)January 14, 2025 | markets.businessinsider.comFate Therapeutics, Inc. (NASDAQ:FATE) CEO Bahram Valamehr Sells 8,705 SharesJanuary 14, 2025 | insidertrades.comCAR Natural Killer Cell Therapy Shows Promise in B-Cell LymphomasJanuary 13, 2025 | msn.comFate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in StockFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) CEO Bahram Valamehr sold 8,705 shares of the business's stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $1.54, for a total transaction of $13,405.70. Following the completion of the sale, the chief executive officer now owns 349,364 shares of the company's stock, valued at approximately $538,020.56. The trade was a 2.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.January 13, 2025 | marketbeat.comFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of "Hold" from AnalystsFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has been assigned an average recommendation of "Hold" from the ten research firms that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating oDecember 28, 2024 | marketbeat.comInsider Buying: Fate Therapeutics, Inc. (NASDAQ:FATE) Director Purchases 397,964 Shares of StockDecember 27, 2024 | insidertrades.comFate Therapeutics, Inc. (NASDAQ:FATE) Director Acquires $668,579.52 in StockFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) Director Redmile Group, Llc bought 397,964 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were bought at an average cost of $1.68 per share, with a total value of $668,579.52. Following the completion of the purchase, the director now directly owns 12,884,277 shares in the company, valued at $21,645,585.36. This represents a 3.19 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.December 26, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short InterestFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 11,350,000 shares, a growth of 9.2% from the November 15th total of 10,390,000 shares. Based on an average daily volume of 2,250,000 shares, the short-interest ratio is currently 5.0 days.December 17, 2024 | marketbeat.comBarclays Gives a Buy Rating to Fate Therapeutics (FATE)December 12, 2024 | markets.businessinsider.comHold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy DevelopmentDecember 11, 2024 | markets.businessinsider.comFate Therapeutics presents new data from FT819 studyDecember 10, 2024 | markets.businessinsider.comFate Therapeutics presents new data from FT819 studyDecember 10, 2024 | markets.businessinsider.comFate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus ErythematosusDecember 9, 2024 | globenewswire.comPiper Sandler Remains a Buy on Fate Therapeutics (FATE)December 6, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Veeva Systems (VEEV) and Alcon (ALC)December 6, 2024 | markets.businessinsider.comFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by AnalystsShares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average recommendation of "Hold" from the ten brokerages that are covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold recommendation and three have issued a buy recommDecember 3, 2024 | marketbeat.comFate Therapeutics, Inc.: Fate Therapeutics Announces Leadership TransitionNovember 30, 2024 | finanznachrichten.deFate Therapeutics Taps Bob Valamehr to Be CEONovember 29, 2024 | marketwatch.comFate Therapeutics CEO Wolchko to retireNovember 29, 2024 | markets.businessinsider.comFate Therapeutics Announces Leadership TransitionNovember 29, 2024 | globenewswire.comVestal Point Capital LP Has $5.90 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)Vestal Point Capital LP lowered its stake in Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 15.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,685,000 shares of the biopharmaceutical company's stock after seNovember 29, 2024 | marketbeat.comFate Therapeutics, Inc. (NASDAQ:FATE) Short Interest UpdateFate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 10,390,000 shares, a drop of 34.7% from the October 31st total of 15,900,000 shares. Based on an average daily trading volume, of 1,930,000 shares, the short-interest ratio is currently 5.4 days.November 29, 2024 | marketbeat.comFate Therapeutics to Present at Upcoming December Investor ConferencesNovember 26, 2024 | globenewswire.comFate Therapeutics' SWOT analysis: clinical progress boosts stock outlookNovember 23, 2024 | uk.investing.comPositive Clinical Developments and Promising Outcomes Propel Fate Therapeutics’ Growth PotentialNovember 21, 2024 | markets.businessinsider.comBarclays Releases a Buy Rating on Fate Therapeutics (FATE)November 20, 2024 | markets.businessinsider.comFate stock closes 12% higher after soaring 73% on drug data (update)November 20, 2024 | msn.comFate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment OptionsNovember 20, 2024 | seekingalpha.comStifel ‘impressed’ with results for Fate Therapeutics’ first FT819 LN patientNovember 19, 2024 | markets.businessinsider.comFate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trialNovember 19, 2024 | markets.businessinsider.comFate stock rallies 37% on positive Phase 1 data for FT819, FT522November 19, 2024 | msn.comFate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR ConvergenceNovember 19, 2024 | finance.yahoo.comWall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug DataNovember 19, 2024 | seekingalpha.comNeedham & Company LLC Reaffirms Hold Rating for Fate Therapeutics (NASDAQ:FATE)Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comFate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR ConvergenceNovember 18, 2024 | globenewswire.comFY2024 EPS Estimate for Fate Therapeutics Lowered by AnalystFate Therapeutics, Inc. (NASDAQ:FATE - Free Report) - Analysts at Wedbush reduced their FY2024 earnings per share (EPS) estimates for shares of Fate Therapeutics in a research report issued to clients and investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that thNovember 15, 2024 | marketbeat.comFate Therapeutics Unveils Q3 2024 Financial HighlightsNovember 14, 2024 | markets.businessinsider.comOptimistic Outlook for Fate Therapeutics Amid Promising Cell Therapy DevelopmentsNovember 14, 2024 | markets.businessinsider.comCautious Hold Rating for Fate Therapeutics Amidst Clinical Uncertainties and Financial StabilityNovember 14, 2024 | markets.businessinsider.comFate Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 14, 2024 | finance.yahoo.comAnalysts Are Neutral on These Healthcare Stocks: Fate Therapeutics (FATE), BridgeBio Pharma (BBIO)November 13, 2024 | markets.businessinsider.comConservative Hold Rating for Fate Therapeutics Amid Early Pipeline Development and Unclear Competitive EdgeNovember 13, 2024 | markets.businessinsider.comFate Therapeutics (FATE) Receives a Buy from BarclaysNovember 13, 2024 | markets.businessinsider.comFate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Fate Therapeutics in a report on Wednesday.November 13, 2024 | marketbeat.comFate Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 12, 2024 | globenewswire.com Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address FATE Media Mentions By Week FATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FATE News Sentiment▼0.590.50▲Average Medical News Sentiment FATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FATE Articles This Week▼104▲FATE Articles Average Week Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Erasca News ORIC Pharmaceuticals News Tectonic Therapeutic News VectivBio News Kura Oncology News CARGO Therapeutics News Pharvaris News Humacyte News Annexon News Keros Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FATE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts